JP2018523978A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523978A5
JP2018523978A5 JP2017564379A JP2017564379A JP2018523978A5 JP 2018523978 A5 JP2018523978 A5 JP 2018523978A5 JP 2017564379 A JP2017564379 A JP 2017564379A JP 2017564379 A JP2017564379 A JP 2017564379A JP 2018523978 A5 JP2018523978 A5 JP 2018523978A5
Authority
JP
Japan
Prior art keywords
bacterium
induced
deficiency
gene
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017564379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523978A (ja
JP6817966B2 (ja
Filing date
Publication date
Priority claimed from US14/960,333 external-priority patent/US9487764B2/en
Priority claimed from PCT/US2016/020530 external-priority patent/WO2016141108A1/en
Application filed filed Critical
Priority claimed from PCT/US2016/034200 external-priority patent/WO2016200614A2/en
Publication of JP2018523978A publication Critical patent/JP2018523978A/ja
Publication of JP2018523978A5 publication Critical patent/JP2018523978A5/ja
Application granted granted Critical
Publication of JP6817966B2 publication Critical patent/JP6817966B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017564379A 2015-06-10 2016-05-25 高アンモニア血症に関連する疾患を治療するために操作された細菌 Expired - Fee Related JP6817966B2 (ja)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US201562173710P 2015-06-10 2015-06-10
US201562173706P 2015-06-10 2015-06-10
US62/173,706 2015-06-10
US62/173,710 2015-06-10
US201562183935P 2015-06-24 2015-06-24
US62/183,935 2015-06-24
US201562184770P 2015-06-25 2015-06-25
US201562184811P 2015-06-25 2015-06-25
US62/184,811 2015-06-25
US62/184,770 2015-06-25
US201562248805P 2015-10-30 2015-10-30
US62/248,805 2015-10-30
US201562256041P 2015-11-16 2015-11-16
US201562256039P 2015-11-16 2015-11-16
US201562256048P 2015-11-16 2015-11-16
US62/256,041 2015-11-16
US62/256,048 2015-11-16
US62/256,039 2015-11-16
US201562263329P 2015-12-04 2015-12-04
US14/960,333 2015-12-04
US14/960,333 US9487764B2 (en) 2014-12-05 2015-12-04 Bacteria engineered to treat diseases associated with hyperammonemia
US62/263,329 2015-12-04
US201662277654P 2016-01-12 2016-01-12
US62/277,654 2016-01-12
US201662291468P 2016-02-04 2016-02-04
US62/291,468 2016-02-04
US201662293749P 2016-02-10 2016-02-10
US62/293,749 2016-02-10
USPCT/US2016/020530 2016-03-02
PCT/US2016/020530 WO2016141108A1 (en) 2015-03-02 2016-03-02 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
PCT/US2016/034200 WO2016200614A2 (en) 2015-06-10 2016-05-25 Bacteria engineered to treat diseases associated with hyperammonemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020217391A Division JP2021061846A (ja) 2015-06-10 2020-12-25 高アンモニア血症に関連する疾患を治療するために操作された細菌

Publications (3)

Publication Number Publication Date
JP2018523978A JP2018523978A (ja) 2018-08-30
JP2018523978A5 true JP2018523978A5 (https=) 2019-06-20
JP6817966B2 JP6817966B2 (ja) 2021-01-20

Family

ID=57504262

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017564379A Expired - Fee Related JP6817966B2 (ja) 2015-06-10 2016-05-25 高アンモニア血症に関連する疾患を治療するために操作された細菌
JP2020217391A Pending JP2021061846A (ja) 2015-06-10 2020-12-25 高アンモニア血症に関連する疾患を治療するために操作された細菌

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020217391A Pending JP2021061846A (ja) 2015-06-10 2020-12-25 高アンモニア血症に関連する疾患を治療するために操作された細菌

Country Status (5)

Country Link
EP (1) EP3307879A2 (https=)
JP (2) JP6817966B2 (https=)
AU (1) AU2016274311A1 (https=)
CA (1) CA2988930A1 (https=)
WO (1) WO2016200614A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136795A1 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases associated with tryptophan metabolism
MX2019014027A (es) * 2017-05-24 2020-08-03 Thoeris Gmbh Uso de glutamina sintetasa para tratar hiperamonemia.
AU2018379996A1 (en) * 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
CN110446259B (zh) * 2018-05-04 2022-04-15 大唐移动通信设备有限公司 一种寻呼机会的位置确定方法及通信设备
KR20220003030A (ko) 2019-04-29 2022-01-07 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수
WO2020239882A1 (en) 2019-05-30 2020-12-03 Recordati Industria Chimica E Farmaceutica S.P.A. Pharmaceutical formulation for carglumic acid
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
US12290540B2 (en) 2019-11-29 2025-05-06 Jinis Co., Ltd Strain having ability to lower blood ammonia levels and composition comprising same for neuronal protection
EP3839051A1 (en) * 2019-12-19 2021-06-23 Evonik Operations GmbH Method for the fermentative production of guanidinoacetic acid
EP4256039A2 (en) 2020-12-02 2023-10-11 Synlogic Operating Company, Inc. Engineered microorganisms
TWI813236B (zh) 2021-03-31 2023-08-21 日商日本製鐵股份有限公司 無方向性電磁鋼板、無方向性電磁鋼板的衝孔方法及無方向性電磁鋼板的衝孔用模具
CN119592452B (zh) * 2024-11-23 2025-12-02 清华大学 洋葱伯克霍尔德菌及其浸出废料中稀土元素的方法
CN120000813A (zh) * 2025-02-17 2025-05-16 温州医科大学 工程益生菌在防治阿尔茨海默病中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3083315B2 (ja) * 1990-10-29 2000-09-04 株式会社ヤクルト本社 血中アンモニア低下剤
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
AU3108400A (en) 1998-12-02 2000-06-19 Trustees Of Boston University Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
WO2009123029A1 (ja) * 2008-03-31 2009-10-08 株式会社 大塚製薬工場 血中アンモニア調整剤
CA2926466C (en) * 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2018523978A5 (https=)
JP6768689B2 (ja) 高アンモニア血症に関連する病気を処置するために操作された細菌
JP7407120B2 (ja) シンバイオティクス組成物
Schöpping et al. Stress response in bifidobacteria
US20210095297A1 (en) Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier
Nanda et al. Impact of spontaneous prophage induction on the fitness of bacterial populations and host-microbe interactions
JP6817966B2 (ja) 高アンモニア血症に関連する疾患を治療するために操作された細菌
EP3307870B1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
JP2018515106A5 (https=)
CA2978315A1 (en) Bacteria engineered to produce butyrate under low oxygen or anaerobic conditions and uses thereof
JP2020525012A5 (https=)
EP3227440B1 (en) Bacteria engineered to treat diseases associated with hyperammonemia
Xu et al. Metabolic engineering of Lactococcus lactis for high level accumulation of glutathione and S-adenosyl-L-methionine
WO2016210378A2 (en) Multi-layered control of gene expression in genetically engineered bacteria
EP3541942B1 (en) Conjugative vectors selectable by fructooligosaccharides
Sulek et al. Metabolic footprint of Lactobacillus acidophilus NCFM at different pH
Jeong et al. Lactobacillus plantarum LRCC5314 Includes a Gene for a Substance that Stimulates the Secretion of Serotonin
RU2799354C2 (ru) Синбиотические композиции
KAUR et al. Mechanism of Endogenous Oxalate Synthesis and Its Degradation by Probiotic Bacteria in Humans.
CA3097270C (en) Synbiotic compositions
Sun et al. Safety and probiotic characterization of Lacticaseibacillus rhamnosus SAL2: insights from integrated genomics and functional validation
Shen The Role of Gut Microbiota Urease in the Host With Liver Disease
AU2024287571A1 (en) Modified bacterium having anti-tumor activity and better safety
HK40038440B (en) Synbiotic compositions
HK40038440A (en) Synbiotic compositions